Bio-Techne Corporation (TECH)
NASDAQ: TECH · Real-Time Price · USD
52.83
+2.68 (5.34%)
Aug 12, 2025, 4:00 PM - Market closed
Paramount Global Revenue
In the fiscal year ending June 30, 2025, Bio-Techne had annual revenue of $1.22B with 5.23% growth. Bio-Techne had revenue of $316.96M in the quarter ending June 30, 2025, with 3.55% growth.
Revenue (ttm)
$1.22B
Revenue Growth
+5.23%
P/S Ratio
6.82
Revenue / Employee
$399,880
Employees
3,050
Market Cap
8.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.22B | 60.58M | 5.23% |
| Jun 30, 2024 | 1.16B | 22.36M | 1.97% |
| Jun 30, 2023 | 1.14B | 31.10M | 2.81% |
| Jun 30, 2022 | 1.11B | 174.57M | 18.75% |
| Jun 30, 2021 | 931.03M | 192.34M | 26.04% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TECH News
- 6 days ago - Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Bio-Techne beats quarterly estimates on strength in protein sciences unit - Reuters
- 6 days ago - BIO-TECHNE DECLARES DIVIDEND - PRNewsWire
- 6 days ago - Bio-Techne Releases Fourth Quarter Fiscal 2025 Results - PRNewsWire
- 7 days ago - Bio-Techne Announces Exosome Diagnostics Divestiture - PRNewsWire
- 7 days ago - ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine - PRNewsWire
- 12 days ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 12 days ago - ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering - PRNewsWire